Aranesp study results

"A large, multicenter, randomized, placebo-controlled study has shown that darbepoetin alfa, marketed as Aranesp, failed in cancer patients who have anemia not caused by chemotherapy. The study also showed higher mortality in patients who received the product. "Aranesp is not approved for use in this population," Sean Harper, MD, senior vice president of global development and corporate chief medical officer at Amgen, emphasized in a letter to healthcare professionals. "Aranesp is approved for the treatment of patients with anemia that is caused by chemotherapy treatment of their malignant disease, rather than the underlying malignant disease itself."

...for the full text see:

Medscape http://www.medscape.com/viewarticle/551450?src=mp